title: Increase in covalent binding of 5-hydroxydiclofenac to hepatic tissues in rats co-treated with lipopolysaccharide and diclofenac: involvement in the onset of diclofenac-induced idiosyncratic hepatotoxicity.
abstract: Diclofenac (DCF), a nonsteroidal anti-inflammatory drug, is well known to induce idiosyncratic hepatotoxicity. Although there remains much to be elucidated about its onset mechanism, it is widely accepted as a hypothesis that idiosyncratic hepatotoxicity arises from a specific immune response to a hapten formed by covalent binding of drugs or their reactive metabolites to hepatic tissues. In this study, we investigated the effects of covalent binding of DCF reactive metabolites to hepatic tissues using a rat model of liver injury induced by co-treatment with lipopolysaccharide (LPS) at a non-hepatotoxic dose. In studies done in vitro using hepatic microsomes prepared from rats treated with LPS alone, 4'- and 5-hydroxylation activities on DCF metabolism and adducts of reactive metabolites to dansyl glutathione (dGSH) were markedly decreased associated with a decrease in total P450 content. However, in studies done in vivo, the LPS/DCF co-treatment significantly increased adducts of 5-hydroxydiclofenac (5-OH-DCF) to rat hepatic tissues and delayed the elimination of 5-OH-DCF from plasma. Furthermore, we investigated the effects of co-treatment on hepatic GSH level in rats. A decrease of hepatic GSH was observed with the LPS/DCF co-treatment but not with LPS or DCF alone. The results suggest that covalent binding of reactive metabolites via 5-OH-DCF to hepatic tissues may play an important role in the onset of DCF-induced idiosyncratic hepatotoxicity, especially under decreased GSH conditions.
authors.affiliation: Safety Research Laboratory, R&D, Kissei Pharmaceutical Co., Ltd, Nagano, Japan. tomoyuki_kishida@pharm.kissei.co.jp
authors.forename: Tomoyuki
authors.initials: T
authors.lastname: Kishida
authors.forename: Tomoya
authors.initials: T
authors.lastname: Onozato
authors.forename: Toru
authors.initials: T
authors.lastname: Kanazawa
authors.forename: Satoru
authors.initials: S
authors.lastname: Tanaka
authors.forename: Junji
authors.initials: J
authors.lastname: Kuroda
mesh_terms: D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage* / Q000378:metabolism / Q000633:toxicity*; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology*; D003577:Cytochrome P-450 Enzyme System / Q000378:metabolism; D004008:Diclofenac / Q000008:administration & dosage* / Q000031:analogs & derivatives* / Q000378:metabolism / Q000633:toxicity*; D004195:Disease Models, Animal; D005978:Glutathione / Q000378:metabolism; D006900:Hydroxylation; D066298:In Vitro Techniques; D008070:Lipopolysaccharides / Q000008:administration & dosage* / Q000633:toxicity*; D008099:Liver / Q000378:metabolism*; D008297:Male; D008862:Microsomes, Liver / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D008070:Lipopolysaccharides; D004008:Diclofenac; D003577:Cytochrome P-450 Enzyme System; D005978:Glutathione; C117715:5-hydroxydiclofenac